The medicine will cost $2,185 a vial in the US, according to the company. The US Food and Drug Administration (FDA) gave Elan and its US partner Biogen Idec Inc. permission to re-introduce the treatment this week.
Tysabri, which is administered 13 times a year, will cost $28,400 a year per patient, up from $23,500 previously.
An estimated 2.5 million people worldwide have multiple sclerosis, a neurological disorder that erodes muscle coordination and balance, resulting in paralysis and impaired vision in some patients.
Tysabri was withdrawn on February 28, 2005 after three people contracted progressive multifocal leukoencephalopathy, a disease that killed two of them.
Elan's shares are down 45 cent to €11.90 in early afternoon trading in Dublin.
In a statement, Elan said that Tysabri (natalizumab) will be available upon the completion of key activities related to the risk management plan, including finalization of educational and training materials, internal validation of systems based on final FDA requirements and training of internal personnel. As such, Elan and Biogen Idec anticipate Tysabri will be available in July.
The wholesale acquisition cost is $2184.62 per vial.
Elan and Biogen Idec are committed to making TYSABRI accessible to appropriate patients who may benefit from therapy. To achieve this goal, programs have been developed to assist patients who are uninsured or who require financial assistance, the statement said.
© Copyright 2007 by Finfacts.com